Tsumura & Co
TSE:4540
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
|
Tsumura & Co
TSE:4540
|
300.3B JPY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
960.1B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
284.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.1B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
235.3B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
158B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.2B USD |
Loading...
|
Market Distribution
| Min | -122 700% |
| 30th Percentile | 2.9% |
| Median | 5.4% |
| 70th Percentile | 8.5% |
| Max | 63 031.4% |
Other Profitability Ratios
Tsumura & Co
Glance View
Tsumura & Co., a venerable name in the herbal medicine industry, traces its roots back to 1893. Emerging from Japan's rich pharmacopeia tradition, the company has carved a niche by blending age-old herbal knowledge with contemporary research and quality control. This synergy allows Tsumura to thrive in the modern marketplace, offering Kampo—a traditional Japanese herbal medicine—as their primary product line. Tsumura stands out in its meticulous approach to sourcing high-quality raw materials, employing state-of-the-art technology to ensure efficacy and safety. This rigorous quality assurance not only honors the integrity of traditional formulas but also aligns with the stringent standards of modern healthcare. In its pursuit of growth, Tsumura expertly navigates the delicate balance between tradition and innovation. The company generates revenue through the sale of its Kampo products, which are widely used in clinics and hospitals across Japan, reflecting a significant integration into the mainstream healthcare system. Additionally, Tsumura's strategic collaborations with pharmaceutical companies expand its reach into international markets. Through educational initiatives, they further advocate for the understanding and acceptance of herbal medicine globally. By continually investing in research and development, Tsumura aims to bolster their product offerings, ensuring that the ancient wisdom of Kampo remains relevant in today's fast-paced, health-conscious world.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Tsumura & Co is 15.1%, which is above its 3-year median of 13.3%.
Over the last 3 years, Tsumura & Co’s Net Margin has decreased from 15.2% to 15.1%. During this period, it reached a low of 9.4% on Sep 30, 2023 and a high of 17.9% on Mar 31, 2025.